Rubicon Research Limited
Fidelity cut its stake in Rubicon Research from 1.42% to 1.23%, selling 3,11,082 shares [1.22]. Its holding decreased to 20,39,772 shares [1.22].
A pharmaceutical company engaged in the development, manufacturing, and commercialization of differentiated drug formulations across multiple therapeutic areas. Incorporated in 1999, the company specializes in creating specialized formulations that address specific medical needs in the Indian healthcare market. Its integrated operations span research and development, manufacturing of quality pharmaceuticals, and distribution. The company distinguishes itself through its focus on bringing innovative, differentiated solutions to patients and healthcare providers.
Boston-based global active asset manager with India exposure through emerging market and India-focused funds.